Actively Recruiting
Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)
Led by Mỹ Đức Hospital · Updated on 2025-09-25
790
Participants Needed
2
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this randomized clinical trial is to evaluate the effectiveness of the letrozole-stimulated cycle strategy versus the artificial cycle strategy for endometrial preparation in women with irregular menstrual cycles after one cycle of endometrial preparation. The primary question it aims to answer is: • Does the letrozole-stimulated cycle strategy for endometrial preparation result in a higher live birth rate compared to the artificial cycle strategy in women with irregular menstrual cycles after one cycle of endometrial preparation? Participants will undergo screening before endometrial preparation for frozen embryo transfer, following which they will be randomly assigned to one of two groups: LETS or AC. In the LETS group, investigators will prescribe letrozole 5 milligrams/day for 5 days to stimulate follicular development and micronized progesterone 800 milligrams/day for luteal phase support. In contrast, the AC group will receive oral estradiol valerate 6-12 milligrams/day and micronized progesterone 800 milligrams/day. Researchers will compare the LETS and AC groups to determine if there are differences in live birth rates.
CONDITIONS
Official Title
Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 - 42.
- Irregular menstrual cycle (less than 21 days or more than 35 days or fewer than 8 cycles per year).
- Indicated for endometrial preparation.
- Transfer of only one blastocyst.
- Not participating in any other trials.
You will not qualify if you...
- Allergy to letrozole, Ovitrelle, oral estradiol valerate, or micronized progesterone.
- Having embryos from oocyte donation or pre-implantation genetic testing cycles.
- Presence of ovarian cysts unrelated to oocyte pick-up.
- Diagnosed with recurrent pregnancy loss or recurrent implantation failure.
- Endometrial abnormalities such as hyperplasia, intrauterine adhesions, polyps, or chronic endometritis.
- Uterine abnormalities including certain fibroids, adenomyosis, or congenital uterine malformations.
- Untreated hydrosalpinx.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
My Duc Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 70000
Actively Recruiting
2
My Duc Phu Nhuan Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 70000
Actively Recruiting
Research Team
N
Nam T Nguyen, MD.
CONTACT
V
Vu NA Ho, MD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here